Zhou Yu, Zhou Geyu, Tian Chenfei, Jiang Waner, Jin Ling, Zhang Chenyu, Chen Xi
State Key Laboratory of Pharmaceutical Biotechnology, Collaborative Innovation Center of Chemistry for Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, NJU Advanced Institute for Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, China.
Wiley Interdiscip Rev RNA. 2016 Nov;7(6):758-771. doi: 10.1002/wrna.1363. Epub 2016 May 16.
Small RNAs, including small interfering RNAs (siRNA) and microRNAs (miRNA), are emerging as promising therapeutic drugs against a wide array of diseases. The key obstacle for the successful clinical application of small RNAs is to develop a safe delivery system directed at the target tissues only. Current small RNA transfer techniques use viruses or synthetic agents as delivery vehicles. The replacement of these delivery vehicles with a low toxicity and high target-specific approach is essential for making small RNA therapy feasible. Because exosomes have the intrinsic ability to traverse biological barriers and to naturally transport functional small RNAs between cells, they represent a novel and exciting delivery vehicle for the field of small RNA therapy. As therapeutic delivery agents, exosomes will potentially be better tolerated by the immune system because they are natural nanocarriers derived from endogenous cells. Furthermore, exosomes derived from genetically engineered cells can deliver small RNAs to target tissues and cells. Thus, exosome-based delivery of small RNAs may provide an untapped, effective delivery strategy to overcome impediments such as inefficiency, nonspecificity, and immunogenic reactions. In this review, we briefly describe how exosomal small RNAs function in recipient cells. Furthermore, we provide an update and overview of new findings that reveal the potential applications of exosome-based small RNA delivery as therapeutics in clinical settings. WIREs RNA 2016, 7:758-771. doi: 10.1002/wrna.1363 For further resources related to this article, please visit the WIREs website.
包括小干扰RNA(siRNA)和微小RNA(miRNA)在内的小RNA,正逐渐成为治疗多种疾病的有前景的治疗药物。小RNA成功临床应用的关键障碍是开发仅针对靶组织的安全递送系统。当前的小RNA转移技术使用病毒或合成剂作为递送载体。用低毒性和高靶向特异性方法替代这些递送载体对于使小RNA治疗可行至关重要。由于外泌体具有穿越生物屏障并在细胞间自然运输功能性小RNA的内在能力,它们代表了小RNA治疗领域一种新颖且令人兴奋的递送载体。作为治疗递送剂,外泌体可能会被免疫系统更好地耐受,因为它们是源自内源性细胞的天然纳米载体。此外,源自基因工程细胞的外泌体可以将小RNA递送至靶组织和细胞。因此,基于外泌体的小RNA递送可能提供一种尚未开发的有效递送策略,以克服诸如低效、非特异性和免疫原性反应等障碍。在本综述中,我们简要描述了外泌体小RNA在受体细胞中的功能。此外,我们提供了新发现的更新和概述,这些发现揭示了基于外泌体的小RNA递送作为临床治疗方法的潜在应用。WIREs RNA 2016, 7:758 - 771。doi: 10.1002/wrna.